Study of Teprenone in the Treatment of Glucocorticoid-Induced Drug-Related Gastrointestinal Injury

Inclusion criteria

• Age 18 to 70 years;
• Patients diagnosed with systemic lupus erythematosus (SLE) meeting the 2019 EULAR/ACR classification criteria for SLE;
• Receiving moderate to high doses of glucocorticoids (prednisone or its equivalent 30-60 mg , once daily);
• Voluntarily participate in this study and sign the informed consent form.

Exclusion criteria

• Presence of other gastric mucosal lesions, such as active ulcers, active bleeding, gastric cancer, gastric polyps, etc.;
• History of subtotal gastrectomy;
• History of endoscopic treatments, such as Endoscopic Submucosal Dissection (ESD) or Endoscopic Mucosal Resection (EMR);
• Significant psychiatric and behavioral abnormalities or mood disorders;
• History of clinically significant diseases, including: Chronic congestive heart failure (NYHA Class IV); History of echocardiography-confirmed ejection fraction (EF) < 30%; Myocardial infarction, acute coronary syndrome, viral myocarditis, or pulmonary embolism within 6 months; Coronary revascularization within 6 months; Severe arrhythmia requiring treatment with Class Ia or III antiarrhythmic drugs;History of sick sinus syndrome, Mobitz II and Complete Heart Block without a permanent pacemaker implanted; QTc interval≥480 ms on screening ECG;
• Laboratory abnormalities at screening as follows: Total bilirubin > 3 times ULN (Upper Limit of Normal); AST/ALT > 3 times ULN; Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m²;
• Currently receiving treatment (e.g., chemotherapy, radiotherapy, immunotherapy) for other malignancies;
• Pregnant or lactating women;
• Allergy or hypersensitivity to the study drug(s).